Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.

Authors
Type
Published Article
Journal
Leukemia Research
0145-2126
Publisher
Elsevier
Publication Date
Volume
36
Issue
7
Pages
803–803
Identifiers
DOI: 10.1016/j.leukres.2012.03.016
PMID: 22502918
Source
Medline

Statistics

Seen <100 times